Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|March 25, 2021
Immunotherapy revolutionizes frontline treatment in advanced RCC
Author(s)Urology Times staff
Advertisement
Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5